Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1985-4-3
pubmed:abstractText
The antibacterial activity of the new quinolone compounds enoxacin, norfloxacin, ofloxacin and ciprofloxacin was evaluated in 300 Enterobacteriaceae, 50 Pseudomonas aeruginosa, 30 Acinetobacter spp., 15 Haemophilus influenzae, 50 Streptococcus faecalis, and 70 Staphylococcus aureus isolates and compared to that of nalidixic acid, gentamicin and various beta-lactam compounds. Moreover, the rate of spontaneous mutants resistant to quinolone compounds was evaluated. In concentrations only insignificantly exceeding the minimal inhibitory concentrations (MIC), mutants could be isolated rather frequently (approx. 10(-6) fold); in concentrations of at least 10 times the MIC resistant mutants were barely detectable. In general, the mutants exhibited a 4- to 8-fold increase of the MIC as compared to the wild strain. In S. faecalis mutants were not detectable, whereas they occurred in low frequency (less than 10(-8) fold) in S. aureus strains. In all mutants there was almost, but not entirely, complete cross-resistance between the quinolone derivatives.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Ampicillin, http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cefotaxime, http://linkedlifedata.com/resource/pubmed/chemical/Ciprofloxacin, http://linkedlifedata.com/resource/pubmed/chemical/Enoxacin, http://linkedlifedata.com/resource/pubmed/chemical/Gentamicins, http://linkedlifedata.com/resource/pubmed/chemical/Mezlocillin, http://linkedlifedata.com/resource/pubmed/chemical/Nalidixic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Naphthyridines, http://linkedlifedata.com/resource/pubmed/chemical/Norfloxacin, http://linkedlifedata.com/resource/pubmed/chemical/Ofloxacin, http://linkedlifedata.com/resource/pubmed/chemical/Oxazines, http://linkedlifedata.com/resource/pubmed/chemical/Quinolines
pubmed:status
MEDLINE
pubmed:issn
0009-3157
pubmed:author
pubmed:issnType
Print
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
19-28
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed-meshheading:3156025-Acinetobacter, pubmed-meshheading:3156025-Ampicillin, pubmed-meshheading:3156025-Anti-Bacterial Agents, pubmed-meshheading:3156025-Bacteria, pubmed-meshheading:3156025-Cefotaxime, pubmed-meshheading:3156025-Ciprofloxacin, pubmed-meshheading:3156025-Enoxacin, pubmed-meshheading:3156025-Enterobacteriaceae, pubmed-meshheading:3156025-Enterococcus faecalis, pubmed-meshheading:3156025-Gentamicins, pubmed-meshheading:3156025-Haemophilus influenzae, pubmed-meshheading:3156025-Mezlocillin, pubmed-meshheading:3156025-Nalidixic Acid, pubmed-meshheading:3156025-Naphthyridines, pubmed-meshheading:3156025-Norfloxacin, pubmed-meshheading:3156025-Ofloxacin, pubmed-meshheading:3156025-Oxazines, pubmed-meshheading:3156025-Penicillin Resistance, pubmed-meshheading:3156025-Pseudomonas aeruginosa, pubmed-meshheading:3156025-Quinolines, pubmed-meshheading:3156025-Staphylococcus aureus
pubmed:year
1985
pubmed:articleTitle
Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
pubmed:publicationType
Journal Article, Comparative Study